Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
β-SPECIFIC 4: Canakinumab Tapering in SJIA
NCT02296424Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2014
- Primary completion
- Oct 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of canakinumab in systemic juvenile idiopathic arthritis (SJIA), sponsored by Novartis. Started Nov 2014; status: completed.
02
Drugs
canakinumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on NCT02296424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02296424.